Acute Toxicities and Short-Term Follow-up of 31 Patients Treated with Intensity-Modulated Proton Beam Radiotherapy (IMPT) for Unresectable Hepatocellular Carcinoma (HCC): A Single-Institution, Two Campus Experience
R.S. Bhangoo(Mayo Clinic Hospital), Terence T. Sio(The University of Texas MD Anderson Cancer Center), J.B. Ashman(Mayo Clinic Hospital), Jaden D. Evans(Mayo Clinic), William G. Rule(Mayo Clinic in Arizona), Trey C. Mullikin(Cancer Institute (WIA)), T.A. DeWees(Mayo Clinic in Arizona), Kay Pepin(Mayo Clinic), Michael A. Golafshar, Christopher L. Hallemeier(Mayo Clinic in Arizona), Michael G. Haddock(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), C. Liu(Mayo Clinic Hospital), Tiffany Cheng(Mayo Clinic in Florida), Thomas Byrne(WinnMed), W. Liu(Mayo Clinic Hospital)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2019
Cited by 0
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)
|Journal of Clinical Oncology|2008|270